Publicaciones en las que colabora con CRISTINA JIMÉNEZ LUNA (20)

2023

  1. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer

    International journal of nanomedicine, Vol. 18, pp. 5075-5093

  2. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review

    Metabolites, Vol. 13, Núm. 7

  3. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis

    NMR in Biomedicine, Vol. 36, Núm. 9

2022

  1. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

    Biomedicine and Pharmacotherapy, Vol. 155

2021

  1. Circulating ptgs2, jag1, gucy2c and pgf mrna in peripheral blood and serum as potential biomarkers for patients with metastatic colon cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 11

  2. Impact of the epigenetically regulated hoxa-5 gene in neural differentiation from human adipose-derived stem cells

    Biology, Vol. 10, Núm. 8

  3. Temozolomide: An updated overview of resistance mechanisms, nanotechnology advances and clinical applications

    Current Neuropharmacology, Vol. 19, Núm. 4, pp. 513-537

2020

  1. Differentiation of human mesenchymal stem cells towards neuronal lineage: Clinical trials in nervous system disorders

    Biomolecules and Therapeutics, Vol. 28, Núm. 1, pp. 34-44

  2. Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics

    Cancers, Vol. 12, Núm. 4

  3. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression

    Journal of Biosciences, Vol. 45, Núm. 1

  4. Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents

    AAPS PharmSciTech, Vol. 21, Núm. 5

2019

  1. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

    Cancer Biology and Medicine, Vol. 16, Núm. 4, pp. 688-699

  2. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Proteomic biomarkers in body fluids associated with pancreatic cancer

    Oncotarget, Vol. 9, Núm. 23, pp. 16573-16587

2017

  1. Untargeted LC-HRMS-based metabolomics for searching new biomarkers of pancreatic ductal adenocarcinoma: A pilot study

    SLAS Discovery, Vol. 22, Núm. 4, pp. 348-359

2016

  1. Current status of immunotherapy treatments for pancreatic cancer

    Journal of Clinical Gastroenterology, Vol. 50, Núm. 10, pp. 836-848

  2. Last advances in nanocarriers-based drug delivery systems for colorectal cancer

    Current Drug Delivery, Vol. 13, Núm. 6, pp. 830-838

2014

  1. Application of nanotechnology in the treatment and diagnosis of gastrointestinal cancers: Review of recent patents

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Núm. 1, pp. 21-34

  2. CO-17 Estudio de MGMT, MMR y P-gp como posibles meca-nismos de resistencia a la temozolamida en líneas tumoralesde glioblastoma

    I Congreso Nacional Multidisciplinar de Jóvenes Investigadores: libro de Actas : Facultad de Ciencias, Universidad de Granada 19, 20 y 21 de febrero de 2014 (Asociación de Investigadores Extranjeros (AINVEX)), pp. 55-59

  3. Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

    Digestive Diseases and Sciences, Vol. 59, Núm. 11, pp. 2714-2720